Company: VRCA
Filing Date: 2025-12-15
Form Type: S-3
Source: 0001193125-25-319225
Chunk: 4

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-15
Form: S-3
Chunk 4
---

should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference,
regardless of the time of delivery of this prospectus, or any sale of our common stock. Our business, financial condition and results of operations may have changed since those dates.

Throughout this prospectus, the terms “we,” “us,” “our,” and our “company” refer to Verrica
Pharmaceuticals Inc. and its subsidiaries.

ii

PROSPECTUS SUMMARY

This summary highlights certain information about us, the Private Placement and selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of our company, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement, including the factors described under the heading “Risk Factors” on page 4 of this prospectus, as well as the information incorporated herein by reference, before making an investment decision.

Company Overview

We are a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. Our commercial
product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. Our current product portfolio consists of one approved product with several potential follow-on
indications, as well as additional pipeline products.

Our commercial product, YCANTH (VP-102),
was approved by the U.S. Food and Drug Administration in July 2023 for the treatment of molluscum contagiosum, or molluscum, in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a
proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are currently developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Our second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment
of dermatology oncologic conditions, including basal cell carcinoma.

Implications of Being a Smaller Reporting Company and a Non-AcceleratedFiler

We are a “smaller reporting company,” as defined in Rule 12b-2 of the Securities Exchange Act of 1934